Ruoxinlin / Ansofaxine: SNDRI Pending FDA Approval

Toludesvenlafaxine (trade names: Ruoxinlin, Ansofaxine) is in stage III of US clinical trials and may become the first triple reuptake inhibitor / SNDRI (serotonin-norepinephrine-dopamine reuptake inhibitor) to come to market for the treatment of depression, anxiety, and other mental health conditions.
--
This channel represents my small attempt to reduce the stigma surrounding depression and anxiety, particular among younger males. If you're curious about me, or want to get in touch, please feel free to do so via my personal website (danielrosehill.com) or through my main CZcams channel (danielrosehill.com/youtube).

[@Kris_USA90]

Cannot wait to give this a shot!!

[@Wedmarco1]

Sertraline / Zoloft is a SDRI, just a pretty unbalanced one with 86 fold selectivity for serotonin compared to dopamine…

[@DanielSRosehill]

I read that for it to have any significant dopaminergic activity you're looking at OCD level dosages (ie, about the FDA approved limit). Not sure if that's accurate but yeah ... the dopamine affinity is very, very modest.

[@nenadcubric2663]

It didnt do anything to my anxiety

[@deepdive5092]

Also, Sertraline (and fluoxetine) are the only SSRIs with an active metabolite! 😁👍🧠

[@jasond626]

When's it out in the UK?